Usefulness of combination therapy with Daclatasvir plus Asunaprevir in chronic hepatitis C patients with chronic kidney disease.
Norihiko MorisawaYohei KoshimaJun-Ichi SatohYukio MaruyamaSatoru KuriyamaTakashi YokooMorimasa AmemiyaPublished in: Clinical and experimental nephrology (2016)
Combination therapy with DCV plus ASV for chronic HCV genotype 1b infection is useful and tolerable, not only in patients with normal eGFR, but also in those with CKD with declined eGFR. Viral eradication at an early phase of the treatment appears to be faster in CKD patients.
Keyphrases
- combination therapy
- chronic kidney disease
- end stage renal disease
- hepatitis c virus
- small cell lung cancer
- epidermal growth factor receptor
- tyrosine kinase
- ejection fraction
- newly diagnosed
- prognostic factors
- sars cov
- peritoneal dialysis
- patient reported outcomes
- helicobacter pylori infection
- patient reported
- hiv infected
- antiretroviral therapy